The 340B PATIENTS Act of 2025 would clarify that drug manufacturers must offer 340B discounts regardless of how or where a covered outpatient drug is dispensed. It would bar certain conditions manufacturers might place on covered entities and apply these rules when entities use contract pharmacies. The bill would also allow civil monetary penalties for intentional violations and require a process for covered entities to report violations.
Covered entities, such as hospitals, clinics, and health centers, could use contract pharmacies to dispense drugs bought at 340B prices. The bill does not describe direct changes for individual patients, but its stated purpose is to help covered entities use program savings to provide care and services.
The bill does not provide a cost estimate or an appropriation. It would allow penalties of up to $2 million per day for certain intentional violations by manufacturers.
The bill's findings say that 340B discounts help covered entities stretch limited resources, serve more patients, and provide broader care. They also state that contract pharmacies can help patients access specialty drugs.
No publicly available information.